Leukemia and Lymphoma

While treatment with allogeneic hematopoietic cell transplantation (allo-HCT) showed improved disease-free survival compared with conventional consolidation chemotherapy, the findings suggest there may not be an overall survival (OS) benefit with allo-HCT for patients with intermediate-risk acute myeloid leukemia (AML) during first complete remission.

Coverage from the 64th Annual American Society of Hematology Meeting and Exposition, December 10-13, 2022, New Orleans, Louisiana.

Despite overall improvements in survival outcomes in recent decades, disparities in survival outcomes persist among children and young adults with acute lymphocytic leukemia (ALL) across racial and ethnic groups.

A panel of experts discuss the provider, payer, and patient challenges that must be considered with BTK inhibitors in chronic lymphocytic leukemia, mantle cell lymphoma, and small lymphocytic lymphoma.

Callie Coombs, MD, discusses recent changes you have seen in the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and small lymphocytic lymphoma (SLL) and provides an overview of the Bruton tyrosine kinase inhibitor landscape for CLL, MCL, and SLL.

New data from the POLARIX STUDY show that substituting polatuzumab vedotin for 1 part of a classic first-line chemotherapy combination to manage diffuse large B-cell lymphoma improved progression-free survival without compromising health-related quality-of-life.

Results presented during the 64th American Society of Hematology Annual Meeting and Exposition could offer an effective option for those with relapsed or refractory DLBCL, even as chimeric antigen receptor T-cell therapy becomes standard of care for many patients.

In abstracts presented at the 64th American Society of Hematology Annual Meeting and Exposition, the investigational BTK inhibitor pirtobrutinib showed promising efficacy and safety in several types of B-cell lymphoma.

A panel of experts discuss the most important goals of therapy for patients with chronic lymphocytic leukemia, mantle cell lymphoma, and small lymphocytic lymphoma and the largest unmet needs in leukemia/lymphoma.

Brian Koffman, MD, and Callie Coombs, MD, provide the prevalence and incidence rates of chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and small lymphocytic lymphoma (SLL), and describe how the diagnosis and management of CLL/MCL/SLL impacts a patient’s quality of life.

Callie Coombs, MD, and Brian Koffman, MD, provide an overview of chronic lymphocytic leukemia, mantle cell lymphoma, and small lymphocytic lymphoma, and explore the key differences between these disease states.

A recent study aggregated RNA sequencing data from more than 3000 samples to create a user-friendly database of transcription profiles in leukemia and related cell lines.

The broad approval, while expected, will likely signal a milestone in the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

The study authors said the method also has the advantages of having a quick turnaround and a relatively low cost.

The case is believed to be just the second reported in the scientific literature.

Research presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition examined how certain patient and demographic characteristics that may be related to socioeconomic disparities impact the risk of hematological cancers; the influence of diabetes on chronic myeloid leukemia; and 2 updates on ponatinib.

Two abstracts reviewed venetoclax, the first FDA-approved BCL-2 inhibitor in acute myeloid leukemia (AML) and a novel BCL-2 inhibitor to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

The approval makes mosunetuzumab the first in its class approved to treat follicular lymphoma and comes shortly after data from a phase 2 trial was presented at the annual meeting of the American Society of Hematology.

The top 5 most-read content in leukemia and lymphoma for 2022 addressed chimeric antigen receptor T-cell therapy, updates in recommended treatment, and President Joe Biden’s announcement on the return of the Cancer Moonshot.

The top news out of the annual meeting of the American Society of Clinical Oncology (ASCO) highlighted findings in gliobastoma, HER2-low breast cancer, and Hodgkin lymphoma.

The PI3K cell-signaling network has been an important therapeutic target in oncology research for nearly 40 years ago, but the use of PI3K inhibitors in hematologic malignancies has come under scrutiny amid concerns about efficacy and safety.

Bruton tyrosine kinase (BTK) inhibitors are currently the only FDA-approved agents indicated specifically for patients with Waldenström macroglobulinemia.

Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope in Duarte, California, spoke on the influence that the California Cancer Care Equity Act is having on legislative efforts in other states, as well as future steps to promote accessible, affordable, and effective cancer care for patients nationwide.

While chronic lymphocytic leukemia (CLL) typically progresses slowly, awareness of rare but potentially serious complications is crucial to improve outcomes.

Zanubrutinib is the latest of 3 Bruton tyrosine kinase (BTK) inhibitors approved for rare B-cell malignancies, such as Waldenström macroglobulinemia, a non-Hodgkin B-cell lymphoma (NHBCL); as a next-generation BTK inhibitor, zanubrutinib is designed to have less off-target effects.

Recent research suggested the idea of combining chimeric antigen receptor (CAR) T-cell therapy and Bruton’s tyrosine kinase (BTK) inhibitors for certain patients with advanced mantle cell lymphoma (MCL).

Coverage from the Irvine, California, meeting of the Institute for Value-Based Medicine, chaired by Joseph Alvarnas, MD, vice president for government affairs at City of Hope and chief clinical advisor, AccessHope.

Results will be presented at an upcoming medical conference.

A recent review summarized the current landscape of Bruton tyrosine kinase (BTK) inhibitors in both hematological cancers and inflammatory disorders.